Furthermore, if a mutation is found (i.e. in BRCA1/2 or CHEK2) then specific surveillance protocols may be recommended for the mutation carriers (usually for breast and other cancers, because most breast cancer susceptibility genes are associated with a multi-site cancer predisposition). This evidence concerns the gene CHEK2 and breast carcinoma.